BioNxt Solutions Updates on Sublingual Drug Delivery Progress

Vancouver-based BioNxt Solutions Inc. has provided a detailed update regarding its advancements in sublingual drug delivery technologies. The company's primary focus is on developing a sublingual Cladribine film aimed at treating multiple sclerosis. Current progress includes regulatory documentation and the preparation for a human bioavailability study.

In addition to Cladribine, BioNxt is advancing programs for Everolimus and Semaglutide. Everolimus, commonly used in organ transplants and cancer treatment, is being developed in a sublingual format. Meanwhile, the Semaglutide project targets the growing metabolic disease sector.

The company's intellectual property foundation strengthens with patent protection in Europe and Eurasia for its Cladribine technology. Further applications are progressing in the US. These developments support BioNxt’s commitment to leveraging its thin-film platform across various therapeutic areas.